Eva Versteijne
University of Amsterdam
Internal medicineRadiologySurgeryOncologyRandomized controlled trialExternal beam radiotherapyPancreatic tumorChemoradiotherapyMEDLINEEsophageal cancerPancreatic cancerLymph nodeAdenocarcinomaResectable Pancreatic CancerInterobserver VariationNuclear medicinePlanning target volumeBorderline resectablePreoperative chemoradiotherapyNeoadjuvant treatmentTumor motionRadiation therapyClinical trialMedicine
30Publications
11H-index
684Citations
Publications 32
Newest
4016Background: Preoperative chemoradiotherapy (CRT) may improve overall survival in resectable pancreatic cancer (RPC) and borderline resectable pancreatic cancer (BRPC). Long term results are pre...
Source
#2Eva VersteijneH-Index: 11
Last. B. Groot KoerkampH-Index: 18
view all 4 authors...
#1J. Van DongenH-Index: 1
#2Eva VersteijneH-Index: 11
Last. C.H.J. van EijckH-Index: 31
view all 9 authors...
Source
#1Eva VersteijneH-Index: 11
#2J.L. van DamH-Index: 1
Last. I. H. J. T. de HinghH-Index: 26
view all 17 authors...
Source
#1Eva Versteijne (UvA: University of Amsterdam)H-Index: 11
#2Mustafa Suker (EUR: Erasmus University Rotterdam)H-Index: 13
Last. Geertjan van Tienhoven (UvA: University of Amsterdam)H-Index: 33
view all 14 authors...
Objectives To investigate the accrual proportion and patients' reasons for not participating in the PREOPANC trial on neoadjuvant chemoradiotherapy vs. immediate surgery in resectable and borderline resectable pancreatic cancer, and to compare these patients' outcomes with those of patients who had been randomized in the trial. Summary of background data The external validity of multicenter randomized trials in cancer treatment has been criticized for suboptimal non-representative inclusion. In ...
Source
#1Jelle C van Dongen (EUR: Erasmus University Rotterdam)H-Index: 2
#2Mustafa Suker (EUR: Erasmus University Rotterdam)H-Index: 13
Last. Casper H.J. van Eijck (EUR: Erasmus University Rotterdam)H-Index: 72
view all 16 authors...
Objectives To investigate the effect of preoperative chemoradiotherapy on surgical complications in patients after pancreatic resection for (borderline-)resectable pancreatic cancer. Summary of background data Preoperative chemoradiotherapy is increasingly used in patients with (borderline-)resectable pancreatic cancer. Concerns have been raised about the potential harmful effect of any preoperative therapy on the surgical complication rate after pancreatic resection. Methods An observational an...
Source
#2Eva VersteijneH-Index: 11
Last. A. BruynzeelH-Index: 6
view all 5 authors...
Source
#2Fiammetta Soggiu (Royal Free Hospital)H-Index: 4
Last. Mohammad Abu HilalH-Index: 22
view all 17 authors...
Background: Non-randomized studies have investigated multi-agent gemcitabinebased neo-adjuvant therapies (GEM-NAT) in borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC). Treatment sequencing and specific elements of neoadjuvant treatment are still under investigation. The present meta-analysis aims to assess the effectiveness of GEM-NAT on overall survival (OS) in BR-PDAC. Patients and Methods: A meta-analysis of individual participant data (IPD) on GEMNAT for BR-PDAC were performe...
Source
Source
#1Eva Versteijne (UvA: University of Amsterdam)H-Index: 11
#2Mustafa Suker (EUR: Erasmus University Rotterdam)H-Index: 13
Last. Geertjan van Tienhoven (UvA: University of Amsterdam)H-Index: 33
view all 30 authors...
PURPOSEPreoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven.PATIENTS AND METHODSIn th...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.